Table 5 Time to 2 % target prevalence based on antigen-detection diagnostics. Mean ± SD of program duration (in years) required to reach a target Schistosoma haematobium infection prevalence ≤ 2 % (T(f C , τ)). The panels and intervention values are the same as in Table 4 but using worm antigen-test diagnostics to identify post-treatment infection prevalence
A. | Community-wide MDA Coverage- High-risk village | |||||
Interval | 50Â % | 60Â % | 70Â % | 80Â % | 90Â % | 100Â % |
0.5 | 12 ± 6.5 | 7.5 ± 5.5 | 4.5 ± 0.5 | 3.5 ± 0.5 | 3 ± 0.5 | 2.5 ± 0.5 |
0.75 | > 30 | 22.5 ± 9 | 11 ± 7 | 7.5 ± 5.5 | 4.5 ± 1 | 3.5 ± 0.5 |
1 | > 30 | > 30 | 27.5 ± 6.5 | 15 ± 9 | 8.5 ± 5.5 | 5 ± 1 |
1.25 | > 30 | > 30 | > 30 | 27.5 ± 6.5 | 18 ± 10.5 | 8.5 ± 5.5 |
1.5 | > 30 | > 30 | > 30 | > 30 | 27.5 ± 6.5 | 17 ± 10 |
1.75 | > 30 | > 30 | > 30 | > 30 | > 30 | 24.5 ± 8.5 |
2 | > 30 | > 30 | > 30 | > 30 | > 30 | > 30 |
2.25 | > 30 | > 30 | > 30 | > 30 | > 30 | > 30 |
2.5 | > 30 | > 30 | > 30 | > 30 | > 30 | > 30 |
2.75 | > 30 | > 30 | > 30 | > 30 | > 30 | > 30 |
3 | > 30 | > 30 | > 30 | > 30 | > 30 | > 30 |
á…Ÿ | á…Ÿ | á…Ÿ | á…Ÿ | á…Ÿ | á…Ÿ | á…Ÿ |
B. | School-based MDA Coverage- Low-risk village | |||||
Interval | 50Â % | 60Â % | 70Â % | 80Â % | 90Â % | 100Â % |
0.5 | 17.5 ± 13. | 16 ± 13.5 | 14 ± 13.5 | 13 ± 13.5 | 11 ± 13. | 10.5 ± 13. |
0.75 | 24.5 ± 9.5 | 19.5 ± 12. | 17.5 ± 13. | 16 ± 13. | 14 ± 13.5 | 13.5 ± 14. |
1 | > 30 | 26 ± 8.5 | 21 ± 11.5 | 19 ± 12.5 | 16.5 ± 13. | 15.5 ± 13.5 |
1.25 | > 30 | > 30 | 26 ± 8.5 | 21.5 ± 11. | 19 ± 12.5 | 17.5 ± 13. |
1.5 | > 30 | > 30 | 29 ± 4. | 26 ± 8.5 | 21 ± 11. | 19 ± 12.5 |
1.75 | > 30 | > 30 | > 30 | 29 ± 4.5 | 25.5 ± 9.5 | 20 ± 11.5 |
2 | > 30 | > 30 | > 30 | > 30 | 28 ± 6. | 23.5 ± 10. |
2.25 | > 30 | > 30 | > 30 | > 30 | > 30 | 25.5 ± 9. |
2.5 | > 30 | > 30 | > 30 | > 30 | > 30 | 28 ± 6.5 |
2.75 | > 30 | > 30 | > 30 | > 30 | > 30 | > 30 |
3 | > 30 | > 30 | > 30 | > 30 | > 30 | > 30 |